Tim Demuth

Tim Demuth

Company: Pieris AG

Job title: Chief Medical Officer


Tumor Localized Immune Activation with PRS-343 (4-1BB-HER2 bispecific) – From Concept to Clinical Efficacy 2:30 pm

Localized 4-1BB agonism leads to robust activation of T cells PRS-343 is safe and well tolerated PRS-343 shows clinical activity in Gastric Cancer patients (Phase 1 data)Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.